Nobuyoshi Hiraoka
YOU?
Author Swipe
View article: Simultaneous activation of STING and lymphotoxin β receptor potentiates immune checkpoint inhibition and prevents tumor recurrence and metastasis by inducing germinal center B cell responses in TLS 4774
Simultaneous activation of STING and lymphotoxin β receptor potentiates immune checkpoint inhibition and prevents tumor recurrence and metastasis by inducing germinal center B cell responses in TLS 4774 Open
Description We found that simultaneous activation of innate immune effectors, STING and lymphotoxin-b receptor (LTbR), using their agonists induces intratumoral germinal center B cell responses to generate functional TLS in mouse tumors. S…
View article: Unexpectedly High Incidence of Immune‐Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab‐Including Chemotherapy
Unexpectedly High Incidence of Immune‐Related Adverse Events in Gastric Cancer Patients Who Received Conversion Surgery After Nivolumab‐Including Chemotherapy Open
Background Nivolumab‐including chemotherapy (nivo‐CTX) for stage IV gastric cancer (GC) may increase the chance of conversion surgery but risk of immune‐related adverse events (irAEs) during perioperative period remains unclear. Methods We…
View article: Impact of ERCC1 on the outcomes of chemotherapy in advanced biliary tract cancer
Impact of ERCC1 on the outcomes of chemotherapy in advanced biliary tract cancer Open
View article: Supplementary Figure S10 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S10 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S10. IHC staining of macrophages in the tumor treated with alectinib and anti-PD-L1 inhibitor. A
View article: Data from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Data from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Tyrosine kinase inhibitors are initially efficacious against anaplastic lymphoma kinase (ALK) fusion gene–positive lung adenocarcinoma, but acquired resistance inevitably occurs. Therefore, alternative treatment strategies are neede…
View article: Simultaneous STING and lymphotoxin-β receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity
Simultaneous STING and lymphotoxin-β receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity Open
B cell-rich tertiary lymphoid structures (TLS) are associated with favorable prognosis and positive response to immunotherapy in cancer. Here we show that simultaneous activation of innate immune effectors, STING and lymphotoxin-β receptor…
View article: Supplementary Figure S11 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S11 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S11. IL-6 produced by cancer cells decreases CD8+T cell-attractant chemokine gene expression and induces MDSC.
View article: Supplementary Table S1 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Table S1 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Table S1
View article: Supplementary Figure S2 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S2 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S2. CD8+ T cell-attractant chemokine gene expression in UMAP plots of single-cell RNA-sequencing analysis.
View article: Supplementary Table S2 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Table S2 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Table S2
View article: Supplementary Figure S12 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S12 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S12. EML4-ALK activates the RAS/MAPK/AP-1 signaling pathway.
View article: Supplementary Figure S3 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S3 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S3. Method to generate macrophages and the phenotype of the macrophages.
View article: Supplementary Figure S8 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S8 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S8. Gating strategies for mouse immune cell types.
View article: Supplementary Figure S5 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S5 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S5.MDSC-abundant TME in fusion gene-positive LUAD.
View article: Supplementary Figure S6 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S6 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S6. The strategy of MDSC induction by cancer cells.
View article: Supplementary Figure S9 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S9 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S9. Immunohistochemical (IHC) staining of PD-1+ and PD-L1+ cells, and macrophages in the tumor.
View article: Supplementary Figure S7 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S7 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S7. The suppressive activity of induced MDSC.
View article: Supplementary Figure S4 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S4 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
SupplementaryFigureS4.TheexpressionofdendriticcellmarkersandCD8+Tcell-attractantchemokines in macrophages induced by GM-CSF.
View article: Supplementary Figure S1 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer
Supplementary Figure S1 from EML4–ALK Rearrangement Creates a Distinctive Myeloid Cell–Dominant Immunosuppressive Microenvironment in Lung Cancer Open
Supplementary Figure S1. Gating strategies for human immune cell types.
View article: Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a post hoc analysis of JCOG1213
Prognostic factors for overall survival in advanced digestive neuroendocrine carcinoma treated with first-line cisplatin-based chemotherapy: a post hoc analysis of JCOG1213 Open
Background: There is no consensus on prognostic factors for advanced digestive neuroendocrine carcinoma (ADNEC). JCOG1213 was a phase III randomized trial that demonstrated equivalent overall survival (OS) between cisplatin plus etoposide …
View article: Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy
Prevalence of HER3 Expression in Pancreatic Cancer Patients Treated With Systemic Chemotherapy Open
Background Although activation of human epidermal growth factor receptor 3 (HER3) is linked to resistance to targeted therapies in several cancer types, the HER3 expression profile during pancreatic cancer treatment remains unknown. Aims W…
View article: Utility of Transpapillary Biopsy and Endoscopic Ultrasound-Guided Tissue Acquisition for Comprehensive Genome Profiling of Unresectable Biliary Tract Cancer
Utility of Transpapillary Biopsy and Endoscopic Ultrasound-Guided Tissue Acquisition for Comprehensive Genome Profiling of Unresectable Biliary Tract Cancer Open
Tissue sampling in biliary tract cancer (BTC) is generally performed through transpapillary biopsy (TPB) or endoscopic ultrasound-guided tissue acquisition (EUS-TA). For the first time, we compared the suitability of specimens obtained usi…
View article: Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial Open
PURPOSE Treatment options for patients with unresectable or recurrent biliary tract cancer (BTC) who progress on a gemcitabine-containing regimen are limited. In addition, the significance of anti–human epidermal growth factor receptor 2 (…
View article: The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology
The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology Open
Patients with rare cancer preferentially benefited from tumor mutation profiling by increasing the chances of therapeutic response to matched therapies. Early-line treatments after profiling increase the therapeutic benefit, irrespective o…
View article: Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments
Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments Open
Overcoming resistance to immune checkpoint inhibitors is an important issue in patients with non‐small‐cell lung cancer (NSCLC). Transcriptome analysis shows that adenocarcinoma can be divided into three molecular subtypes: terminal respir…
View article: Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer
Predictive and prognostic value of excision repair cross-complementing group 1 in patients with advanced gastric cancer Open
Background To define the optimal chemotherapy regimen for each patient we therefore used tissue from patients to identify molecular prognostic or predictive biomarkers. Methods Endoscopic biopsy specimens from primary lesions and surgical …
View article: Diagnostic performance of EUS-guided tissue acquisition for solid pancreatic lesions ≤10 mm
Diagnostic performance of EUS-guided tissue acquisition for solid pancreatic lesions ≤10 mm Open
Background and Objectives EUS tissue acquisition (EUS-TA) is the standard diagnostic method for solid pancreatic lesions (SPLs); however, there are few reports on EUS-TA results for SPLs ≤10 mm. Furthermore, given the recent advent of fine…
View article: Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report
Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case report Open
View article: Predictive and prognostic value of excision repair cross-complementing group 1 by multi-omics on the outcomes in patients with advanced gastric cancer
Predictive and prognostic value of excision repair cross-complementing group 1 by multi-omics on the outcomes in patients with advanced gastric cancer Open
Background To define the optimal chemotherapy regimen for each patient we therefore used tissue from patients to identify molecular prognostic or predictive biomarkers. Methods Endoscopic biopsy specimens from primary lesions and surgical …
View article: DNA methylation alterations of <i>ADCY5</i>, <i>MICAL2</i>, and <i>PLEKHG2</i> during the developmental stage of cryptogenic hepatocellular carcinoma
DNA methylation alterations of <i>ADCY5</i>, <i>MICAL2</i>, and <i>PLEKHG2</i> during the developmental stage of cryptogenic hepatocellular carcinoma Open
Aim The aim of this study was to clarify the significance of DNA methylation alterations of cryptogenic hepatocellular carcinomas (HCCs). Methods Using the Infinium assay, we performed genome‐wide DNA methylation analysis of 250 liver tiss…